New drug trial aims to control bleeding disorder
NCT ID NCT06754852
Summary
This early-stage study is testing a new drug called HMB-002 in adults with Von Willebrand Disease, a genetic bleeding disorder. The main goals are to check if the drug is safe, determine the right dose, and see if it helps reduce bleeding episodes. Researchers will first test single doses, then move to repeated doses in people who experience frequent bleeding.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fiona Stanley Hospital
NOT_YET_RECRUITINGMurdoch, Perth, WA 6150, Australia
-
Richmond Pharmacology
RECRUITINGLondon, SE1 1YR, United Kingdom
-
Royal Prince Alfred Hospital
RECRUITINGCamperdown, Sydney, NSW 2050, Australia
-
The Alfred Hospital
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
Conditions
Explore the condition pages connected to this study.